Bioceres Crop Solutions Earnings Call Transcripts
Fiscal Year 2026
-
Revenue fell 17% year-over-year to $77.5 million, but gross margin expanded to 47% and adjusted EBITDA rose 61% due to cost reductions. Segment margins improved, though seed and crop protection revenues declined. Net debt remained stable amid ongoing debt dispute.
Fiscal Year 2025
-
Fiscal 2025 saw a 28% revenue decline and margin compression due to macroeconomic headwinds in Argentina and a strategic shift in the seed business. Cost controls, working capital improvements, and international growth in core technologies are expected to support recovery and margin expansion as the company transitions to a more scalable model.
-
Q3 saw a $40M year-over-year cash flow improvement despite lower revenues, driven by strategic seed business changes and working capital efficiency. RinoTec’s EPA approval and organizational restructuring position the company for growth, with positive outlooks in key markets.
-
Quarterly revenues fell 24% year-over-year due to Argentina's market contraction, but gross margin improved to 42%. The company is shifting to an asset-light, royalty-based model, forming new partnerships and focusing on cost efficiency and global expansion.
-
Q1 revenue fell 20% year-over-year due to drought in Argentina, but gross margin improved to nearly 40%. International growth, regulatory wins, and a strategic shift in HB4 commercialization support optimism for the rest of the year.
Fiscal Year 2024
-
Record revenues and EBITDA were achieved despite challenging ag markets, with Q4 sales up 18% and strong growth in HB4 and biologicals. Strategic pivots, new leadership, and capacity investments position the company for profit-focused expansion in FY25.